Emerging Frontiers: T-Cell Engagers, Radioligands, and BCR скачать в хорошем качестве

Emerging Frontiers: T-Cell Engagers, Radioligands, and BCR

A regional roundtable discussion, moderated by Jingsong Zhang, MD, PhD, Moffitt Cancer Center, explored evolving treatment strategies in advanced prostate cancer, including the integration of ARPIs, PARP inhibitors, radioligand therapy, and novel immunotherapies. Dr. Zhang was joined by other practitioners in the greater Tampa area, including Nuruddin Jooma, MD, MPH, Florida Cancer Specialists & Research Institute; Jad Chahoud, MD, MPH, Moffitt Cancer Center; and Vikas Malhotra, MD, Florida Cancer Specialists & Research Institute. In the final segment, the panel concludes with a forward-looking discussion on emerging therapies and strategies for prostate cancer. The panelists highlight the promise of earlier use of ARPIs with ADT, radioligand therapy, CAR-T, and T-cell engagers, while noting that neuroendocrine and small cell variants remain a significant unmet need that requires careful monitoring and innovative treatment approaches.